Credent Connect N Care Approves 26% Kartavya Healtheon Stake
Key highlights
- Credent approved the acquisition of a 26% stake in Kartavya Healtheon on 17 November 2026.
- Kartavya Healtheon reported FY2025-26 turnover of ₹59.18 crore.
- The transaction includes a secondary purchase of 6% shares, fresh equity subscription and loan conversion.
- Credent's earlier ₹4.5 crore loan carried an option to acquire up to 26% equity in Kartavya Healtheon.
powered by IRIS

On 17 November 2026, Credent Connect N Care Ltd approved the acquisition of a 26% equity stake in Kartavya Healtheon Pvt Ltd, a healthcare company with FY2025-26 turnover of ₹59.18 crore. The proposed transaction links an earlier ₹4.5 crore inter-corporate loan with an equity investment and is scheduled for completion within three months.
Know Credent Connect N Care inside out
Results, valuation, peers and who's buying, in one view.
What did Credent approve in the Kartavya Healtheon transaction?
Credent approved the acquisition of a 26% stake in Kartavya Healtheon through a combination of a secondary share purchase, a fresh equity subscription and conversion of an inter-corporate loan into shares. The NSE filing does not quantify the total consideration or transaction value.
The company said the cost of acquisition would be based on a report from a Registered Valuer. It also stated that no regulatory approvals are required for the transaction. Completion is expected within three months of the board approval, subject to the steps needed to execute the proposed share purchase, subscription and loan conversion.
Kartavya Healtheon was incorporated on 2 July 2008 and operates in integrated healthcare. Its reported turnover for FY2025-26 was ₹59.18 crore. The disclosed stake will give Credent a minority interest rather than control of the healthcare business.
How did the investment arrangement develop?
The proposed equity acquisition follows Credent's 4 November 2026 board approval for a ₹4.5 crore unsecured inter-corporate loan to Kartavya Healtheon. That arrangement gave Credent the option to acquire up to a 26% equity stake in the borrower.
According to the earlier disclosure, the loan was interest-free until 25 November 2026. Thereafter, it carries interest at 12% a year, compounded monthly. The borrower was to use the funds to repay its outstanding optionally convertible preference shares and other loans.
The 17 November approval formalises the route for Credent to take a 26% holding. The filing specifies that loan conversion is one component of the acquisition, alongside the secondary purchase of 6% equity shares and a fresh subscription. It does not provide the percentage allocated to the fresh subscription or loan conversion.
This structure allows existing shares to change hands while new shares may be issued by Kartavya Healtheon. The valuation basis is disclosed, but the absence of a stated consideration means investors cannot calculate the implied valuation of the target from the announcement alone.
Got a follow-up? Ask IRIS
What are the financial and market implications for Credent?
The immediate financial effect cannot be quantified because Credent has not disclosed the acquisition consideration, the number of shares involved or the final allocation between the three transaction components. The filing also does not state the accounting treatment, expected earnings contribution or any planned operational integration.
The earlier ₹4.5 crore loan provides a disclosed reference point for the arrangement. Based on figures cited with the 4 November announcement, the loan represented about 2.1% of Credent's FY2025-26 revenue of ₹214 crore and about 10% of its net worth of ₹44 crore. Credent's FY2025-26 profit after tax was stated at ₹18 crore.
The reported 12% annual loan rate could have created interest income if the loan remained outstanding after 25 November 2026. However, the approved conversion into shares means the final income and balance-sheet impact will depend on the transaction documents and the amount of debt converted, neither of which has been disclosed.
Credent's share price rose 3.6% on 5 November, following the earlier loan announcement. No share-price movement linked specifically to the 17 November acquisition approval is provided in the available filing information. Investors therefore have a confirmed transaction timeline but limited data to assess the purchase price or financial return.
Why does Kartavya Healtheon's operating profile matter?
Kartavya Healtheon's ₹59.18 crore FY2025-26 turnover establishes the scale of the business in which Credent plans to hold a minority stake. Its integrated healthcare operations place the investment outside Credent's stated commercial services and supplies classification, making the financial disclosures around valuation and ownership important for assessing the transaction.
The proposed deal is also notable because it combines financing and equity participation. Credent first extended an unsecured loan with an option to acquire equity, then approved the stake acquisition within the same month. The arrangement may reduce the outstanding loan through conversion while giving Credent exposure to Kartavya Healtheon's future performance.
For Kartavya Healtheon, the fresh equity subscription and potential loan conversion may change its funding mix, while the secondary purchase enables an existing shareholder to sell shares. The filing does not identify the selling shareholder, the post-transaction shareholding pattern or whether any governance rights will accompany Credent's 26% stake.
The next disclosed milestone is completion within three months. Further exchange disclosures would be needed to confirm the consideration, final equity allotment, extent of loan conversion and the completed ownership structure.
Conclusion
Credent has approved a 26% minority investment in Kartavya Healtheon using a mix of secondary share acquisition, fresh capital and conversion of an earlier ₹4.5 crore loan. The target's ₹59.18 crore FY2025-26 turnover provides context on its operating scale, but the undisclosed consideration prevents a precise assessment of valuation or near-term financial impact on Credent.
Investors should watch for completion within the stated three-month period and for any subsequent filing that provides the transaction value, post-deal shareholding, shares issued through subscription or conversion, and the remaining status of the inter-corporate loan.


